VIP943
An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP943 Monotherapy in Subjects With Advanced CD123+ Hematologic Malignancies
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 36 patients (estimated)
- Sponsors
- Vincerx Pharma, Inc.
- Tags
- Antibody Drug Conjugate (ADC), Kinesin Spindle Protein (KSP) Inhibitor, CD123
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1769
- NCT Identifier
- NCT06034275
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.